Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922552 | 0.94 | NAAA (0.40) | NAAAHTR1AACACBHCRTR2PTGDR2 | |
| SCHEMBL14766900 | 0.91 | NAAA (0.39) | NAAAHTR1AACACBL3MBTL1HCRTR2 | |
| SCHEMBL14765825 | 0.91 | NAAA (0.39) | NAAAHTR1AACACBL3MBTL1HCRTR2 | |
| SCHEMBL12736605 | 0.91 | NAAA (0.36) | NAAAHTR1AACACBHCRTR2PTGDR2 | |
| SCHEMBL12740210 | 0.91 | NAAA (0.36) | NAAAHTR1AACACBHCRTR2PTGDR2 | |
| SCHEMBL15381759 | 0.90 | NAAA (0.38) | NAAAHTR1AACACBHCRTR2 | |
| SCHEMBL10302578 | 0.90 | NAAA (0.38) | NAAAHTR1AACACBL3MBTL1HCRTR2 | |
| SCHEMBL15381649 | 0.90 | NAAA (0.38) | NAAAHTR1AACACBHCRTR2 | |
| SCHEMBL12223913 | 0.89 | NAAA (0.36) | NAAAHTR1AACACBKDM4EL3MBTL1 | |
| SCHEMBL12718957 | 0.89 | NAAA (0.38) | NAAAHTR1AACACBHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | NAAA 3989/4885HTR1A 591/4885ACACB 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.